MDWD · MediWound Ltd. · Insider Trading

On November 10, 2026, the Reporting Person exercised Series A Warrants to purchase 8,168 ordinary shares at an exercise price of $13.475 per share, paying the aggregate exercise price in cash. The Reporting Person did not sell any of the ordinary shares acquired upon the exercise. No separate price was paid for the Series A Warrants upon exercise. The exercise price is reported in column 2 and in Table I. The amount reported in Column 5 also includes 35,714 ordinary shares underlying restricted share units ("RSUs") that were granted to the Reporting Person on June 7, 2022 and became fully vested on June 7, 2026.

On November 10, 2026, the Reporting Person exercised Series A Warrants to purchase 8,168 ordinary shares at an exercise price of $13.475 per share, paying the aggregate exercise price in cash. The Reporting Person did not sell any of the ordinary shares acquired upon the exercise. No separate price was paid for the Series A Warrants upon exercise. The exercise price is reported in column 2 and in Table I. The amount reported in Column 5 also includes 35,714 ordinary shares underlying restricted share units ("RSUs") that were granted to the Reporting Person on June 7, 2022 and became fully vested on June 7, 2026.

On November 10, 2026, the Reporting Person exercised Series A Warrants to purchase 16,336 ordinary shares at an exercise price of $13.475 per share, paying the aggregate exercise price in cash. The Reporting Person did not sell any of the ordinary shares acquired upon the exercise. No separate price was paid for the Series A Warrants upon exercise. The exercise price is reported in column 2 and in Table I.

On November 10, 2026, the Reporting Person exercised Series A Warrants to purchase 6,534 ordinary shares at an exercise price of $13.475 per share, paying the aggregate exercise price in cash. The Reporting Person did not sell any of the ordinary shares acquired upon the exercise. No separate price was paid for the Series A Warrants upon exercise. The exercise price is reported in column 2 and in Table I.

On November 10, 2026, the Reporting Person exercised Series A Warrants to purchase 6,534 ordinary shares at an exercise price of $13.475 per share, paying the aggregate exercise price in cash. The Reporting Person did not sell any of the ordinary shares acquired upon the exercise. No separate price was paid for the Series A Warrants upon exercise. The exercise price is reported in column 2 and in Table I.

On November 10, 2026, the Reporting Person exercised Series A Warrants to purchase 16,336 ordinary shares at an exercise price of $13.475 per share, paying the aggregate exercise price in cash. The Reporting Person did not sell any of the ordinary shares acquired upon the exercise. No separate price was paid for the Series A Warrants upon exercise. The exercise price is reported in column 2 and in Table I.

The Reporting Person exercised 11,000 stock options on a net (cashless) basis. Shares otherwise issuable upon exercise were withheld to satisfy the aggregate exercise price, resulting in the net issuance of 3,958 ordinary shares to the Reporting Person. All 3,958 ordinary shares received upon the net exercise were sold on the same day as reported in Table I.

The options reported in this row are the remaining outstanding options from a grant of 39,000 options that were granted to the Reporting Person on December 1, 2023 and that have been vesting in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.

The Reporting Person exercised 11,000 stock options on a net (cashless) basis. Shares otherwise issuable upon exercise were withheld to satisfy the aggregate exercise price, resulting in the net issuance of 3,958 ordinary shares to the Reporting Person. All 3,958 ordinary shares received upon the net exercise were sold on the same day as reported in Table I.

The Reporting Person exercised 11,000 stock options on a net (cashless) basis. Shares otherwise issuable upon exercise were withheld to satisfy the aggregate exercise price, resulting in the net issuance of 3,958 ordinary shares to the Reporting Person. All 3,958 ordinary shares received upon the net exercise were sold on the same day as reported in Table I.

The Reporting Person exercised 5,000 stock options on a net (cashless) basis. Shares otherwise issuable upon exercise were withheld to satisfy the aggregate exercise price, resulting in the net issuance of 1,865 ordinary shares to the Reporting Person. All 1,865 ordinary shares received upon the net exercise were sold on the same day as reported in Table I.

The options reported in this row are the remaining outstanding options from a grant of 39,000 options that were granted to the Reporting Person on December 1, 2023 and that have been vesting in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.

The Reporting Person exercised 5,000 stock options on a net (cashless) basis. Shares otherwise issuable upon exercise were withheld to satisfy the aggregate exercise price, resulting in the net issuance of 1,865 ordinary shares to the Reporting Person. All 1,865 ordinary shares received upon the net exercise were sold on the same day as reported in Table I.